Technically Speaking For January 02: Colgate-Palmolive Company (CL), Pacific Biosciences of California, Inc. (PACB)

Colgate-Palmolive Company (CL) sank -0.65% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -20.79% and is now down by -21.11% since start of this year. A look at its monthly performance shows that the stock has recorded a -5.27% fall over the past 30 days. Its equity price dipped by -11.1% over the past three months which led to its overall six-month decrease to stand at -8.16%.

A look at CL technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 39.41 point. Its trading volume has lost -965427 shares compared to readings over the past three months as it recently exchanged 4264573 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 5230000 shares, and this is 0.82 times the normal volume.

The price of Pacific Biosciences of California, Inc. (NASDAQ:PACB) currently stands at $7.4 after it went up by $0.07 or 0.95% and has found a strong support at $7.32 a share. If the PACB price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $7.23 mark would also be bad for the stock as it means that the stock would plunge by 2.3% from its current position. However, if the stock price is able to trade above the resistance point around $7.45, then it could likely surge higher to try and break the upward resistance which stands at $7.49 a share. Its average daily volatility over the past one month stands at 1.62%. The stock has plunged by 1.62% from its 52-weeks high of $7.28 which it reached on Nov. 30, 2018. In general, it is 72.7% above its 52-weeks lowest point which stands at $2.02 and this setback was observed on Feb. 04, 2018.

Analysts have predicted a price target for Pacific Biosciences of California, Inc. (PACB) for 1 year and it stands at an average $7.63/share. This means that it would likely increase by 3.11% from its current position. The current price of the stock has been moving between $7.28 and $7.41. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $6.5. On the other hand, one analyst is super bullish about the price, setting a target as high as $8.

The PACB stock Stochastic Oscillator (%D) is at 56.57%, which means that it is currently neutral. The shares P/S ratio stands at 13.17 which compares to the 8.48 recorded by the industry or the 6.22 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 12.4% over the past five years.

Analysts view Pacific Biosciences of California, Inc. (NASDAQ:PACB) as a Hold, with 2.6 consensus rating. Reuters surveyed 7 analysts that follow PACB and found that 4 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 2 analyst rating it as a Buy or a Strong Buy while 1 analysts advised investors to desist from buying Pacific Biosciences of California, Inc. (PACB) shares or sell it if they already own it.